Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, October 25, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, October 24, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tejas Savant Maintained (AKYA) at Buy with Decreased Target to $8 on, Oct 24th, 2023
Tejas Savant of Morgan Stanley, Maintained "Akoya Biosciences, Inc." (AKYA) at Buy with Decreased Target from $15 to $8 on, Oct 24th, 2023.
Tejas has made no other calls on AKYA in the last 4 months.
There are 3 other peers that have a rating on AKYA. Out of the 3 peers that are also analyzing AKYA, 0 agree with Tejas's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Tejas
- David Westenberg of "Piper Sandler" Maintained at Buy with Decreased Target to $11 on, Monday, October 16th, 2023
- John Sourbeer of "UBS" Maintained at Strong Buy with Decreased Target to $7 on, Thursday, October 12th, 2023
- Mason Carrico of "Stephens & Co." Reiterated at Buy and Held Target at $16 on, Tuesday, August 8th, 2023
